Founded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
Pannex TherapeuticsPannex Therapeutics is a New York biotechnology company developing small-molecule therapies that block Pannexin 1 channels, initially for chronic neuropathic pain and triple-negative breast cancer. Founded by Panx1 research leader David Bravo and backed by a team with decades of biopharmaceutical drug-development experience, the company has built a patent-protected discovery platform with hundreds of rationally designed blockers. Its work aims to address shared neuroinflammatory and immune-signaling mechanisms across neurological disease and cancer.New York, NY
Neuraly IncFounded by drug-delivery researcher Seulki Lee after research with Johns Hopkins scientists, Neuraly is a clinical-stage biotechnology company developing medicines for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. Its research centers on glial biology and neuroinflammation, with lead candidate NLY01 advancing through Phase 2 after showing neuroprotective effects in preclinical models. Neuraly operates as a subsidiary of D&D Pharmatech and is guided by scientific co-founders from Johns Hopkins University.GAITHERSBURG, MD
Tactical TherapeuticsFounded in 2005 by cancer scientist and patent attorney Rashida A. Karmali, Tactical Therapeutics is a clinical-stage biopharmaceutical company built around her long career in cancer research, drug development, and intellectual property law. The company develops CTO, an oral therapy designed to reach the brain, for patients with glioblastoma and other cancers that have resisted treatment. Karmali has authored more than 100 scientific publications and holds eight U.S. patents alongside more than 75 international patents.NEW YORK, NY